Why Eli Lilly and Company (LLY) stock moved
Eli Lilly and Company (LLY) shares climbed 6.6% to $1,373.00 as of October 30, 2026, a significant gain from the prior close of $1,288.30. BestStocks flagged the session as a major change for LLY. The move is tied to an earnings beat. Below, we break down what changed for LLY, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
Earnings Beat
LLY climbed 6.6% in its latest session, moving from $1,288.30 to $1,373.00.
What it means for Eli Lilly and Company investors
For Eli Lilly and Company investors, the balance of recent signals points to a strong bullish shift. On the constructive side: Earnings beat with positive market reaction; Strong 6.6% price move with conviction. Weighing against that: New SEC filing — review for material disclosures. Because the move outpaced peers, it looks driven by LLY-specific developments rather than a broad sector rotation. Wall Street's consensus price target sits at $1,359.31, implying -1.0% downside from $1,373.00. BestStocks rates the overall signal quality high (89/100). With earnings roughly 96 days out, the next report is the most likely near-term test of the move.
LLY price reaction
LLY last traded at $1,373.00, up $84.70 (+6.57%) from the previous close of $1,288.30. The session traded on 1.7× average volume (above avg), so the move carried above-average conviction. Its healthcare peer group moved a median +1.7% over the same stretch, leaving LLY ahead of the group by 4.9 points. Over the past month the stock has ranged between $1,142.85 and $1,373.70, and it currently sits about 100% of the way up that band.
Bullish and bearish analyst opinions on Eli Lilly and Company (LLY)
The consensus analyst price target on Eli Lilly and Company (LLY) is $1,359.31, 1.0% below the recent $1,373.00. Over the past 90 days analysts logged 0 upgrades, 11 maintains, and 0 downgrades. Here is how the bullish and bearish cases on LLY line up.
The bullish case
- The Street's most bullish target is $1,500.00 (+9.2%).
- Earnings beat with positive market reaction.
- Strong 6.6% price move with conviction.
- Positive price momentum.
- Eli Lilly surged +2.64% to $1145.17 following a blowout Q2 2026 earnings report (investor.lilly.com).
The bearish case
- The consensus analyst price target of $1,359.31 sits 1.0% below the recent $1,373.00, so the average target sees limited room to run.
- The most bearish analyst target is $940.00 (-31.5%).
Weighing both sides, BestStocks' composite read of recent signals is strongly bullish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Oct 30, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for LLY
In-depth LLY event analyses
Frequently asked questions about LLY
Why did Eli Lilly and Company (LLY) stock move?
LLY climbed 6.6% to $1,373.00. No single company-specific catalyst was confirmed during the move window, and it looks like a company-specific move.
How much did LLY stock rise?
LLY gained 6.57% ($84.70) versus the prior close of $1,288.30, last trading at $1,373.00 on 1.7× average volume.
When is Eli Lilly and Company's next earnings date?
LLY's next earnings report is estimated for 2027-02-03 — about 96 days away.
What is the analyst price target for LLY?
The consensus analyst price target for LLY is $1,359.31, about 1.0% below the current $1,373.00. Over the past 90 days, analysts recorded 0 upgrades, 11 maintains, and 0 downgrades.
Is the LLY move company-specific or sector-wide?
BestStocks classifies it as a company-specific move: the peer group moved a median +1.7% against LLY's +6.6%. LLY ranks top 1 of 7 peers.
How BestStocks tracks LLY
This page is generated automatically by BestStocks' change-detection system after an earnings beat was detected and verified against independent data sources. It draws on 20 tracked change events for LLY, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of October 30, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.